Peter M Kash insider trades: Nile Therapeutics (NLTX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Peter reports to the SEC
and 1 more company
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 12, 2008 | NLTX | ↑ Buy | 4,600 | $1.19 | $5K | Direct | Dec 12, 2008 (0d) |
| Nov 29, 2006 | AMEX:JAV | ↑ Buy | 5,000 | $3.65 | $18K | Direct | Dec 1, 2006 (2d) |
| Jun 9, 2006 | JVPH:OB | ↑ Buy | 100 | $3.00 | $300 | Direct | Jun 14, 2006 (5d) |
| Nov 22, 2005 | JVPH.OB | ↑ Buy | 10,000 | $3.20 | $32K | Direct | Nov 30, 2005 (8d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Peter M Kash's insider trades
Peter M Kash is a director at Nile Therapeutics (NLTX). Since Nov 22, 2005, Peter has reported 4 open-market purchases worth $56K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), other transactions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NLTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.